Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single Dose PD/PK Study of Somatoprim in Healthy Volunteers
NCT02217826Phase 1Completed
- Sponsor
- Aspireo Pharmaceuticals Ltd.
- Primary completion
- Apr 2014
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
Phase 1, randomised, double-blind trial of veldoreotide in acromegaly (3 arms), sponsored by Aspireo Pharmaceuticals Ltd. Primary endpoints: Plasma Glucose Concentration at 4.25 hours, Plasma Insulin Concentration at 4.25 hours and 1 more. Status: completed.
02
Drugs
veldoreotide
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT02217826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02217826.